Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Ivonescimab in Malignant Pleural Mesothelioma: NCT06875076 Clinical Landscape Report 2026
9 min read
Ivonescimab in Malignant Pleural Mesothelioma: NCT06875076 Clinical Landscape Report 2026
16 September 2026
NCT06875076 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
LE-051 in Muscular Dystrophy, Duchenne: NCT06900049 Clinical Landscape Report 2026
9 min read
LE-051 in Muscular Dystrophy, Duchenne: NCT06900049 Clinical Landscape Report 2026
16 September 2026
NCT06900049 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Lung Cancer: NCT06885697 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Lung Cancer: NCT06885697 Clinical Landscape Report 2026
16 September 2026
NCT06885697 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bemiltenase alfa in Hemophilia: NCT06922045 Clinical Landscape Report 2026
9 min read
Bemiltenase alfa in Hemophilia: NCT06922045 Clinical Landscape Report 2026
16 September 2026
NCT06922045 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Emicizumab in Hemophilia A: NCT06938659 Clinical Landscape Report 2026
9 min read
Emicizumab in Hemophilia A: NCT06938659 Clinical Landscape Report 2026
16 September 2026
NCT06938659 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Efanesoctocog alfa in Hemophilia A: NCT06940830 Clinical Landscape Report 2026
9 min read
Efanesoctocog alfa in Hemophilia A: NCT06940830 Clinical Landscape Report 2026
16 September 2026
NCT06940830 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Efanesoctocog alfa in Hemophilia A: NCT06941870 Clinical Landscape Report 2026
9 min read
Efanesoctocog alfa in Hemophilia A: NCT06941870 Clinical Landscape Report 2026
16 September 2026
NCT06941870 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
L-Citrulline in Vaso-occlusive crisis: NCT06989567 Clinical Landscape Report 2026
9 min read
L-Citrulline in Vaso-occlusive crisis: NCT06989567 Clinical Landscape Report 2026
16 September 2026
NCT06989567 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Rilzabrutinib in Anemia, Sickle Cell: NCT06975865 Clinical Landscape Report 2026
9 min read
Rilzabrutinib in Anemia, Sickle Cell: NCT06975865 Clinical Landscape Report 2026
16 September 2026
NCT06975865 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
CS-101 in Acute Chest Syndrome: NCT07000318 Clinical Landscape Report 2026
9 min read
CS-101 in Acute Chest Syndrome: NCT07000318 Clinical Landscape Report 2026
16 September 2026
NCT07000318 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Deferasirox in Complication: NCT07023666 Clinical Landscape Report 2026
9 min read
Deferasirox in Complication: NCT07023666 Clinical Landscape Report 2026
16 September 2026
NCT07023666 clinical landscape for Complication: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
I-131-Apamistamab in Hemoglobin SC Disease: NCT07015684 Clinical Landscape Report 2026
9 min read
I-131-Apamistamab in Hemoglobin SC Disease: NCT07015684 Clinical Landscape Report 2026
16 September 2026
NCT07015684 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →